Form 4 for AGIO AGIOS PHARMACEUTICALS, INC.
Accepted 2022-02-16 00:00:00 ET · period of report 2022-02-14 · accession 0001439222-22-000012 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-02-16 | 2022-02-14 | AGIO | FOUSE JACQUALYN A | CEO, Dir | M - OptEx | $0.00 | +11.3K | 69.7K | +19% | $0 |
| D | 2022-02-16 | 2022-02-14 | AGIO | FOUSE JACQUALYN A | CEO, Dir | F - Tax | $30.50 | -3,505 | 66.2K | -5% | -$106.9K |
| D | 2022-02-16 | 2022-02-14 | AGIO | FOUSE JACQUALYN A | CEO, Dir | M - OptEx | $0.00 | -11.3K | 11.3K | -50% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common stock | 2022-02-14 | M | A | 11,334 | $0.00 | 69,697 | D | — | — | (F1) Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. |
| 2 | Common | Common stock | 2022-02-14 | F | D | 3,505 | $30.50 | 66,192 | D | — | — | |
| 3 | Derivative | Restricted stock units | 2022-02-14 | M | D | 11,334 | $0.00 | 11,333 | D | — · — to — | 11,334 Common stock | (F1) Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. (F2) The restricted stock units were granted on February 14, 2020. Beginning on February 14, 2021, the shares underlying the restricted stock units will vest in three equal annual installments. |